Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Appia Bio Launches with $52 Million Series A Financing and Establishes Scientific Advisory Board
Details : Proceeds from the financing will support the advancement of Appia Bio’s pipeline of allogeneic CAR-iNKT cell therapy candidates into the clinic.
Product Name : CAR-iNKT
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 05, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Kite Pharma
Deal Size : $875.0 million
Deal Type : Collaboration
Details : Collaboration leverages kite’s chimeric antigen receptors and appia bio’s allogeneic cell technology, ACUA platform, for improved efficacy, safety and off-the-shelf accessibility of HSC-derived CAR iNKT-cell therapies.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 08, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Kite Pharma
Deal Size : $875.0 million
Deal Type : Collaboration